Catalent, Inc. (CTLT) EPS Estimated At $0.59

August 13, 2018 - By Billy Entrekin

Catalent, Inc. (NYSE:CTLT) LogoInvestors sentiment decreased to 1.16 in 2018 Q1. Its down 0.28, from 1.44 in 2017Q4. It fall, as 23 investors sold Catalent, Inc. shares while 85 reduced holdings. 37 funds opened positions while 88 raised stakes. 127.42 million shares or 2.50% less from 130.69 million shares in 2017Q4 were reported.
Archford Capital Strategies Limited Liability Company invested in 0% or 81 shares. Natixis Advisors Ltd Partnership has 0.05% invested in Catalent, Inc. (NYSE:CTLT) for 123,642 shares. State Board Of Administration Of Florida Retirement Systems reported 0.01% of its portfolio in Catalent, Inc. (NYSE:CTLT). Tudor Invest Et Al, Connecticut-based fund reported 19,065 shares. 14,500 are held by Ellington Mngmt Gru Ltd Limited Liability Company. Balyasny Asset Management Limited Com reported 0.01% stake. Hsbc Plc, United Kingdom-based fund reported 67,180 shares. State Bank Of Montreal Can stated it has 16,638 shares. Moreover, First Tru L P has 0.02% invested in Catalent, Inc. (NYSE:CTLT). Meeder Asset Mngmt holds 8,110 shares or 0.03% of its portfolio. Amalgamated Comml Bank has invested 0.02% in Catalent, Inc. (NYSE:CTLT). Natixis reported 208,067 shares. Quantbot Technology Ltd Partnership owns 5,589 shares. 291,238 were accumulated by Aqr Management Lc. Rmb Cap Lc invested in 128,461 shares.

Since March 8, 2018, it had 0 insider buys, and 2 selling transactions for $473,717 activity. The insider Downie William sold 9,082 shares worth $379,628.

Analysts expect Catalent, Inc. (NYSE:CTLT) to report $0.59 EPS on August, 28 before the open.They anticipate $0.05 EPS change or 7.81 % from last quarter’s $0.64 EPS. CTLT’s profit would be $85.47 million giving it 17.00 P/E if the $0.59 EPS is correct. After having $0.38 EPS previously, Catalent, Inc.’s analysts see 55.26 % EPS growth. The stock decreased 0.25% or $0.1 during the last trading session, reaching $40.12. About 509,640 shares traded. Catalent, Inc. (NYSE:CTLT) has risen 9.81% since August 13, 2017 and is uptrending. It has underperformed by 2.76% the S&P500.

Catalent, Inc. (NYSE:CTLT) Ratings Coverage

Among 2 analysts covering Catalent (NYSE:CTLT), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Catalent had 2 analyst reports since March 21, 2018 according to SRatingsIntel. Raymond James upgraded Catalent, Inc. (NYSE:CTLT) on Wednesday, March 21 to “Outperform” rating. The company was upgraded on Wednesday, March 28 by KeyBanc Capital Markets.

Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. The company has market cap of $5.81 billion. It operates through three divisions: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. It has a 82.89 P/E ratio. The Softgel Technologies segment offers formulation, development, and manufacturing services for softgels, which are used in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, and unit-dose cosmetics.

Another recent and important Catalent, Inc. (NYSE:CTLT) news was published by Streetinsider.com which published an article titled: “Catalent (CTLT) Sees Q4 Revenue of 683 to $686 Million” on July 23, 2018.

Catalent, Inc. (NYSE:CTLT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.